ClinicalTrials.gg
RecruitingNCT07159620Updated Oct 16, 2026

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

A Phase 2 interventional study of VEN (Venetoclax) and Azacitidine (AZA) in Adult T-cell Leukemia/Lymphoma, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 14 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 16, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
14 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma — 11 open to participants now, 13 under way, 1 of them phase 3. venetoclax · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
10th of 17
27 · median 28
Started
2025
with 5 others
Phase 2
9 of 17
6 open now
Primary completion
2028-09
later than 6 of 12 live
Registered
15th of 17
by date
Lead sponsor
3 of 17
The First Affiliated Hospital of Soochow University

Among the 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, this one is the 10th largest by planned enrollment, is one of 6 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 6 of the 12 other live ones, and was the 15th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

11 of the 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 14 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .

03

Conditions studied

  • Adult T-cell Leukemia/Lymphoma
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
14 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: >14 to 75 years (inclusive).
  2. Diagnosis: Patients diagnosed with ETP-ALL like disease meeting the following flow cytometry immunophenotypic criteria:

    ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate ≤75%, and positive for at least one myeloid/stem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.

    Near-ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate >75%, AND positive for at least one myeloid/stem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.

    T-ALL with myeloid mutations: FLT3, DNMT3A, STAG2, IDH1/IDH2, RUNX1, EZH2, WT1, ASXL1/ASXL2, SF3B1, TET2, BCOR, BCORL1.

  3. Newly diagnosed patients who have not received any prior induction therapy before enrollment (excluding hydroxyurea, dexamethasone, low-dose cytarabine, venetoclax with a cumulative dose \<0.5g, and leukapheresis).
  4. (ECOG) performance status score of 0-2.
  5. Expected survival >6 months.
  6. Demonstrated capacity to understand the study and willingness to provide .

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, breastfeeding, or unwillingness to use in women of
  2. Presence of uncontrolled active infection (including bacterial, fungal, or viral infections); concurrent active , , or infection.
  3. Severe Organ Dysfunction:

    Cardiac Insufficiency: (LVEF) ≤40%, OR history of congestive heart failure, unstable coronary artery disease, or severe arrhythmia.

    Respiratory Failure: Partial pressure of arterial oxygen (PaO₂) ≤60 mmHg. Hepatic Impairment: Total ≥2 times the (ULN), OR (ALT) or aspartate aminotransferase (AST) ≥3 times ULN.

    Renal Impairment: Serum creatinine ≥2 mg/dL, OR ≤30 mL/min/1.73m².

    : History of hypersensitivity to any of the study drugs or compounds of similar chemical structure.

  4. Presence of central nervous system (CNS) leukemia.
  5. Any other condition deemed by the investigator to make the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone

    Induction Therapy Phase: VACVP induction:Venetoclax: 100mg, d1, 200mg, d2, 400mg, d3-d21, orally. Azacitidine,75mg/m²/day, d1-d7, subcutaneously. Chidamide,10mg, d1-d7, orally. Vindesine, 4mg, d1, intravenous infusion. Dexamethasone,9mg/m²/day, d1-d14; reduced by half on d15-d17; further reduced by half on d18-d21, intravenous infusion or orally. Consolidation therapy: 1. alternate use of HD-MTX-Ara C and VACVP(aged 14-65, inclusive of 65); alternate use of reduced-dose MTX-Ara C and VACVP(aged 65-75, inclusive of 75); 2. allogeneic hematopoietic stem cell transplantation (HSCT).

    Drug: VEN (Venetoclax) · Drug: Azacitidine (AZA) · Drug: Chidamide · Drug: vindesine · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Composite Complete Remission Rate(CRc) after induction therapy

    Rates of complete remission (CR), and complete remission with incomplete hematologic recovery (CRi)

    Time frame: Time from the completion of induction and before consolidation therapy(up to 42 days)

Secondary outcomes

  1. Overall survival(OS)

    Time from the date of enrollment to death from any cause or the last follow-up

    Time frame: 2 years

  2. Relapse-Free Survival(RFS)

    The duration from the date of the first complete remisson to the occurrence of relapse, death from any cause, or the last follow-up.

    Time frame: 2 years

  3. duration of remission (DOR)

    Time between the first remission and relapse

    Time frame: 2 years

  4. AE

    Adverse events during the chemotherapy treatment.

    Time frame: Within 30 days after the last chemotherapy

  5. MRD

    Percentage of participants who converted to MRD \< 10\^-4 by flow cytometry

    Time frame: At the end of induction(up to 42 days), 1 cycle of consolidation(up to 42 days), 2 cycle of consolidation (up to 42 days)and the end of consolidation(up to 42 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 40 non-industry phase 2 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 97. This study's planned 36 months is below that.

Counting every sponsor, half of 43 studies reached it within 63 months; a quarter within 39 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 8, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Maximum age 65 Years→75 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAge: >14 to 6575 years (inclusive).
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Eligibility Maximum age 65 Years→75 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge: >14 to 6575 years (inclusive).
    + 3 other changes: verification date, date precision and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07159620
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 1, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Oct 16, 2026

Study contacts

Yang Xu
Contact
xuyang1020@126.com
86+051267781850

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine · Tucidinostat · Vindesine · Dexamethasone

Start the discussion